Antibody-drug conjugates are monoclonal antibodies attached to biologically active drugs
through chemical linkers that deliver and release cytotoxic agents at the tumor site, reducing …

Introduction: All anticancer drugs can cause idiosyncratic liver injury. Therefore,
hepatoprotective agents assume particular importance to preserve liver function. Hepatic …

Over the past decade, the dramatic growth in the number of new prescriptions and over-the-
counter drugs has greatly improved the therapeutic armamentarium but at the expense of an …

Purpose: Adverse reactions reported in patients treated with antibody–calicheamicin
conjugates such as gemtuzumab ozogamicin (Mylotarg) and inotuzumab ozogamicin …

Background and Aims Nodular regenerative hyperplasia (NRH) of the liver is associated
with several diseases and drugs. Clinical symptoms of NRH may vary from absence of …

ABSTRACT Background T-DM1 and T-DXd are two promising antibody-drug conjugates for
treating advanced HER2-positive breast cancer and HER2-mutated lung cancer …

Background Idisyncratic drug‐induced liver injury (DILI) is a rare instance of liver injury after
exposure to an otherwise safe drug or herbal or dietary supplement. DILI can be associated …

Drug-induced nodular regenerative hyperplasia is an uncommon injury with unique
pathophysiology, clinical, and diagnostic considerations. This injury is characteristically …

Highlights•Most common types of drug-induced liver injuries in oncology are presented.•
Hepatotoxicity of chemotherapy and molecular targeted therapies is reviewed.•Imaging …

Background Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for
use in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Case …